R.M. Rudd

3.8k total citations
70 papers, 2.8k citations indexed

About

R.M. Rudd is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, R.M. Rudd has authored 70 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in R.M. Rudd's work include Occupational and environmental lung diseases (25 papers), Pleural and Pulmonary Diseases (20 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (14 papers). R.M. Rudd is often cited by papers focused on Occupational and environmental lung diseases (25 papers), Pleural and Pulmonary Diseases (20 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (14 papers). R.M. Rudd collaborates with scholars based in United Kingdom, United States and France. R.M. Rudd's co-authors include Andrew Johnston, M Turner‐Warwick, P L Haslam, N.H. Gower, P S Hasleton, V. Sundaresan, R L Souhami, N.A. Jarad, G Sinha and Peter Ganly and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

R.M. Rudd

67 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R.M. Rudd United Kingdom 27 2.0k 1.1k 470 336 246 70 2.8k
H. Léna France 20 1.7k 0.8× 1.2k 1.1× 300 0.6× 241 0.7× 234 1.0× 95 2.3k
T Ashcroft United Kingdom 22 2.2k 1.1× 410 0.4× 453 1.0× 409 1.2× 117 0.5× 49 3.3k
Thomas A. Sporn United States 27 2.0k 1.0× 463 0.4× 337 0.7× 203 0.6× 111 0.5× 88 2.7k
Matthew Conron Australia 22 1.7k 0.8× 628 0.6× 308 0.7× 107 0.3× 262 1.1× 54 2.4k
William G. Hocking United States 18 1.4k 0.7× 613 0.6× 222 0.5× 181 0.5× 127 0.5× 48 2.3k
Marie Christine Aubry United States 29 1.4k 0.7× 1.3k 1.2× 598 1.3× 375 1.1× 368 1.5× 102 2.9k
Lary A. Robinson United States 28 1.8k 0.9× 791 0.7× 388 0.8× 212 0.6× 230 0.9× 99 3.0k
James P. Neifeld United States 31 1.0k 0.5× 1.1k 1.0× 236 0.5× 230 0.7× 224 0.9× 71 2.6k
Donald G. Guinee United States 24 784 0.4× 829 0.8× 436 0.9× 489 1.5× 180 0.7× 46 2.1k
Seung Ick South Korea 25 976 0.5× 374 0.4× 626 1.3× 440 1.3× 288 1.2× 181 2.2k

Countries citing papers authored by R.M. Rudd

Since Specialization
Citations

This map shows the geographic impact of R.M. Rudd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.M. Rudd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.M. Rudd more than expected).

Fields of papers citing papers by R.M. Rudd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.M. Rudd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.M. Rudd. The network helps show where R.M. Rudd may publish in the future.

Co-authorship network of co-authors of R.M. Rudd

This figure shows the co-authorship network connecting the top 25 collaborators of R.M. Rudd. A scholar is included among the top collaborators of R.M. Rudd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.M. Rudd. R.M. Rudd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rudd, R.M.. (2010). Malignant mesothelioma. British Medical Bulletin. 93(1). 105–123. 44 indexed citations
2.
Harris, Jessica, Andrew Johnston, R.M. Rudd, A J Newman Taylor, & Paul Cullinan. (2009). Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax. 65(1). 70–76. 63 indexed citations
3.
Lee, Siow Ming, L. E. James, W. Qian, et al.. (2008). Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax. 64(1). 75–80. 48 indexed citations
4.
Rudd, R.M., et al.. (2006). British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax. 62(1). 62–66. 87 indexed citations
5.
Klabatsa, Astero, Michael Sheaff, Jeremy Steele, et al.. (2005). Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM). Lung Cancer. 51(1). 53–59. 48 indexed citations
6.
Mulatero, C, et al.. (2001). A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer. 31(1). 67–72. 26 indexed citations
7.
Cullen, M.H., Lucinda Billingham, C.M. Woodroffe, et al.. (1999). Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life. Journal of Clinical Oncology. 17(10). 3188–3194. 352 indexed citations
8.
Roland, Martín & R.M. Rudd. (1998). Genetics and pulmonary medicine bullet  7: Somatic mutations in the development of lung cancer. Thorax. 53(11). 979–983. 17 indexed citations
9.
O’Byrne, Kenneth J., D. Papamichael, H Robertshaw, et al.. (1998). A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Annals of Oncology. 9(11). 1205–1211. 16 indexed citations
10.
Gower, N.H., R.M. Rudd, SG Spiro, et al.. (1996). A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial. British Journal of Cancer. 73(12). 1563–1568. 20 indexed citations
11.
Miles, David, C. M. Ash, R.M. Rudd, et al.. (1994). Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.. Journal of Clinical Oncology. 12(1). 77–82. 40 indexed citations
12.
Jarad, N.A., et al.. (1993). Bronchoalveolar lavage and 99mTc-DTPA clearance as prognostic factors in asbestos workers with and without asbestosis. Respiratory Medicine. 87(5). 365–374. 7 indexed citations
13.
Ganly, Peter, N.A. Jarad, R.M. Rudd, & Pamela Rabbitts. (1992). PCR-based RFLP analysis allows genotyping of the short arm of chromosome 3 in small biopsies from patients with lung cancer. Genomics. 12(2). 221–228. 36 indexed citations
14.
Festenstein, F., D W Empey, & R.M. Rudd. (1990). Tuberculosis in Britain. BMJ. 300(6735). 1339.3–1339. 1 indexed citations
15.
Craig, Jonathan C., et al.. (1985). A practical guide to clinical oncology. 1. Cancer treatment planning. Veterinary medicine. 80(11). 22–27. 1 indexed citations
16.
Uthayakumar, S, et al.. (1985). Bronchoalveolar lavage and clearance of 99m-Tc-DTPA in asbestos workers without evidence of asbestosis. British Journal of Diseases of the Chest. 79(3). 251–257. 1 indexed citations
17.
Lewis, Christine A., et al.. (1985). Regional distribution of pulmonary epithelial permeability in normal subjects and patients with asbestosis.. Thorax. 40(10). 734–740. 11 indexed citations
18.
19.
Wedzicha, JA, et al.. (1983). Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease.. BMJ. 286(6364). 511–514. 23 indexed citations
20.
Rudd, R.M., et al.. (1980). Fungal endocarditis after homograft valve replacement: difficulties in diagnosis and treatment.. Thorax. 35(9). 686–689. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Léna Breakdown of academic impact, for papers by T Ashcroft Breakdown of academic impact, for papers by Thomas A. Sporn Breakdown of academic impact, for papers by Matthew Conron Breakdown of academic impact, for papers by William G. Hocking Breakdown of academic impact, for papers by Marie Christine Aubry Breakdown of academic impact, for papers by Lary A. Robinson Breakdown of academic impact, for papers by James P. Neifeld Breakdown of academic impact, for papers by Donald G. Guinee Breakdown of academic impact, for papers by Seung Ick
Rankless by CCL
2026